News & Events

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Regulation FD Disclosure On March 12, 2026, Insulet Corporation (the “Company”) issued a press release regarding a voluntary medical device correction. A copy of the press release is furnished herewith as Exhibit 99.1. While it is too early to ascertain the exact cost of the voluntary medical device correction, the Company currently expects to incur up to $40 million of costs associated with this event, all in 2026. These costs will be excluded from adjusted results. Accordingly, Insulet is n…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 27, 2026, Insulet Corporation (the “Company”) entered into a severance agreement and release (the “Severance Agreement”) with Ana M. Chadwick, the Company’s former Chief Financial Officer. The Severance Agreement does not provide for any material compensation or benefits terms that differ from, or are in addition to, those previously dis…

Changes in Registrant’s Certifying Accountant On December 15, 2025, the Audit Committee of the Board of Directors of the Company notified GT, the Company’s then independent registered public accounting firm, that the Audit Committee selected PwC as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. GT was previously engaged to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2025. The…

Regulation FD Disclosure On February 13, 2026, the Board of Directors of Insulet Corporation (the “Company”) approved a $350 million increase in the previously authorized $125 million stock repurchase authorization and extended the authorization through December 31, 2027. With this additional authorization, the total authorization for the repurchase program allows for the purchase of up to $475 million in shares of the Company’s common stock. As of February 16, 2026, the Company has repurchas…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On January 29, 2026, Insulet Corporation (the “ Company ”) and NXP USA, Inc. (“ NXP ”) entered into an Addendum effective January 1, 2026 (the “ 2026 Addendum”) to the Purchase Agreement, dated as of October 12, 2017, between the Company and NXP (the “ Original Agreement ”), as amended. Pursuant to the 2026 Addendum, the term of the Original Agreement, as amended, is extended, and certain terms and conditions related to pricing, product volume, prod…

of Form 8-K of Insulet Corporation dated December 15, 2025, and agree with the statements concerning our Firm contained therein. Very truly yours, GRANT THORNTON LLP 53 State Street, 16th Floor Boston, MA 02109 D +1 617 723 7900 F +1 617 723 6340

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Mark Field, Senior Vice President, Chief Technology Officer of Insulet Corporation (the “ Company ”) left the Company to pursue other opportunities, effective March 14, 2025. As the Company initiates a search for a new Chief Technology Officer, Amit Guliani, currently serving as Group Vice President, Software Engineering, will serve as acting Chief…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 13, 2022, Charles Alpuche, the Executive Vice President, Chief Operating Officer of Insulet Corporation (the “Company”) informed the Company of his decision to retire from this position, effective December 31, 2022. The Company has appointed Prem Singh as Senior Vice President, Global Operations, effective January 1, 2023. Mr. Singh is…

Other Events On July 7, 2022, Insulet Corporation (the “Company”) entered into a Settlement and License Agreement (the “Settlement Agreement”) with Roche Diabetes Care, Inc. (“Roche”) to settle the pending patent infringement lawsuit brought by Roche against the Company. In exchange for a release of claims, mutual covenant not to sue for five years and license to the patent in suit from Roche, the Settlement Agreement provides that the Company will make a one-time payment of $20 million to Ro…

Other Events. On October 4, 2021, Insulet Corporation, a Delaware corporation (the “ Company ”), issued a notice of redemption (the “ Redemption Notice ”) for all of its outstanding 1.375% Convertible Senior Notes due 2024 (the “ Convertible Notes ”). Pursuant to the Redemption Notice, on November 15, 2021 (the “ Redemption Date ”), the Company will redeem any Convertible Notes that have not been converted, redeemed or repurchased prior to such date at a redemption price in cash equal to 100%…

Unregistered Sales of Equity Securities. Insulet Corporation (the “Company” or “Insulet”) previously entered into separate and privately negotiated agreements with certain holders (the “Holders”) of the Company’s outstanding 1.375% Convertible Senior Notes due 2024 (the “Notes”) pursuant to which the Company agreed to repurchase $370,374,000 aggregate principal amount of the Notes (each such transaction, a “Note Repurchase Transaction”) for consideration negotiated separately and privately wi…

Unregistered Sales of Equity Securities On May 13, 2021, Insulet Corporation (the “Company” or “Insulet”) entered into separate and privately negotiated agreements (the “Exchange Agreements”) with certain holders (the “Holders”) of the Company’s outstanding 1.375% Convertible Senior Notes due 2024 (the “Notes”) pursuant to which the Company agreed to repurchase $335,874,000 aggregate principal amount of the Notes (each such transaction, a “Note Repurchase Transaction”) for consideration negot…